In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.Presenters:William G. Wierda, MD, PhD, Program DirectorProfessor of MedicineChief, Section of CLLDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasJeremy S. Abramson, MD, MMScAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Center for LymphomaMassachusetts General HospitalBoston, MassachusettsBrian Hill, MD, PhDDirector, Lymphoid Malignancies ProgramTaussig Cancer InstituteCleveland ClinicCleveland, OhioContent based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.Link to full program, including associated downloadable slidesets:http://bit.ly/3mLjeIb

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related